Mallinckrodt Adderall Lawsuit 2026: What the Court Records Actually Show
Quick Answer
- Legit? No dedicated Adderall settlement is confirmed. Mallinckrodt is a defendant in generic price-fixing litigation that names amphetamine salts.
- How much? Not yet determined. No Mallinckrodt fund, per-person amount, or claim form has been confirmed.
- Deadline? None for Mallinckrodt. A separate generic drug end-payer claim closes November 9, 2026.
There’s no confirmed Mallinckrodt Adderall class action or payout in October 2026. Several sites say otherwise, but none cites a docket number. The name isn’t random, though.
Mallinckrodt is a named defendant in federal generic price-fixing litigation that lists amphetamine salts. Three other drugmakers settled its end-payer claims for $533 million. Mallinckrodt hasn’t joined those deals.
This guide separates the Adderall rumor from the court record. Here’s the surprise: the FDA action people cite involved generic Concerta, not Adderall. You’ll get dates, dollar figures, and the next step.
| The Facts | |
|---|---|
| Case | No dedicated Mallinckrodt Adderall case confirmed. Related: In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL 2724 |
| Status | Pricing litigation pending. Mallinckrodt hasn’t settled the end-payer claims |
| Fund Size | Not yet confirmed for Mallinckrodt ($533 million exists from other defendants) |
| Est. Per Person | Not yet determined |
| Claim Deadline | None for Mallinckrodt. November 9, 2026 for the separate end-payer settlements |
| Administrator | Not yet appointed for Mallinckrodt |
| Proof Needed | Records of covered generic purchases for the end-payer claim |
Is there a Mallinckrodt Adderall lawsuit?
No court has confirmed a dedicated Mallinckrodt Adderall lawsuit as of October 2026.
The only verified case that names Mallinckrodt and amphetamine salts is about pricing. It isn’t about whether the pills work.
Three different things get called “the lawsuit.” Only one is a live federal case.
- Pricing litigation: In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL 2724, in the Eastern District of Pennsylvania. Mallinckrodt is a defendant.
- The FDA dispute: A 2014 fight over Mallinckrodt’s generic Concerta. Different drug, different active ingredient.
- Patient complaints: Online posts saying Mallinckrodt’s tablets feel weaker. No docket number is attached.
Competing pages blur these together. One calls the Adderall suit active and growing without citing a single case number. We couldn’t match that claim to a docket.
Is the Mallinckrodt Adderall lawsuit legit or a scam?
The underlying pricing case is real, but an Adderall payout promise has no record behind it.
Real settlements leave a paper trail. You can trace them to a court, a case number, and a named administrator.
Run any Adderall payout claim through this checklist:
- A case name and number. For the pricing case, it’s 16-MD-2724.
- A court. Here, it’s the U.S. District Court for the Eastern District of Pennsylvania, where Judge Cynthia M. Rufe presides.
- A court-approved notice that spells out who is covered.
- A named settlement administrator and an official claim form.
- A firm claim deadline.
A Mallinckrodt Adderall payout fails tests 3, 4, and 5. None of those documents exists.
Treat any text, email, or ad saying you’re owed Adderall money as a red flag. Class counsel warned the court in November 2025 that some outside claims-recovery firms sent misleading pitches.
Is there a Mallinckrodt Adderall class action?
No class action aimed at Mallinckrodt’s Adderall has been confirmed.
The pricing litigation does include class actions. They were consolidated in the Eastern District of Pennsylvania in August 2016.
Different groups brought different claims:
| Who sued | Who they represent |
|---|---|
| Direct purchasers | Pharmacies, wholesalers, and distributors |
| End payers | Consumers and health plans that paid for generics |
| State attorneys general | 51 states, territories, and the District of Columbia |
Mallinckrodt is on the list of defendants that haven’t settled the end-payer claims. The same list names Teva, Actavis, Amneal, Lupin, and Viatris.
We found no order certifying a class against Mallinckrodt alone. That point isn’t confirmed either way, so check the docket before you rely on it.
Key Takeaway: Mallinckrodt is a pricing-case defendant, not the target of a confirmed Adderall effectiveness lawsuit or class action.
Was Mallinckrodt generic Adderall recalled?
No recall of Mallinckrodt or SpecGx mixed amphetamine salts turned up in the sources we checked.
We didn’t query FDA’s live database for every lot, so check yours. A recall names specific lots, not a whole brand.
People assume a recall because FDA acted against another Mallinckrodt ADHD drug. That drug was generic Concerta.
Recalls of mixed amphetamine salts have happened, but they named other makers:
| Maker | Date | Reason |
|---|---|---|
| Barr Laboratories | August 13, 2009 | Lot 311756, 20 mg tablets, possible overweight (super-potent) tablets |
| Aurobindo Pharma USA | Initiated September 19, 2019 | Super-potency concerns, 20 mg tablets, Class II |
| Teva Pharmaceuticals USA | May 22, 2020 | Some 5 mg bottles may hold mixed strengths, Class II |
Match the lot number on your bottle to FDA’s enforcement reports. Report suspected quality problems through FDA’s MedWatch program.
Is there a Mallinckrodt Adderall settlement?
No Mallinckrodt Adderall settlement is confirmed as of October 12, 2026.
Money is moving in the pricing case, just not from Mallinckrodt. Three finished end-payer settlements total $533 million.
| Settlement | Amount | Final approval |
|---|---|---|
| Sandoz / Fougera | $275 million | September 26, 2025 |
| Sun / Taro | $200 million | January 23, 2026 |
| Apotex / Heritage | $58 million | Late 2025 |
| Total | $533 million |
Mallinckrodt hasn’t joined these deals. Whether it ever will isn’t confirmed.
Watch the phrase “Mallinckrodt settlement” in headlines. It often refers to opioid or Acthar Gel matters. Keenova’s June 2026 quarterly report still carries Acthar Gel settlement liabilities, and none of that money is for Adderall patients.
How much money can you get from the Mallinckrodt Adderall lawsuit?
Not yet determined. No Mallinckrodt Adderall fund exists, so no per-person amount can be calculated.
For the $533 million pool, payments are pro rata. Your share depends on what you paid for covered generics and how many valid claims arrive.
Court-approved fees and costs come out first. No per-person figure has been announced.
| What decides a payout | Status |
|---|---|
| A Mallinckrodt fund | None confirmed |
| What you paid for covered generics | Depends on your records |
| Number of valid claims | Unknown until the November 9 deadline passes |
| Fees and costs | Court approved |
Be wary of anyone quoting dollar amounts for Adderall users. Without a fund and a claims count, any number is a guess.
Reality Check: No one texts you settlement money first, and filing a claim is free. Class counsel told the court that some outside claims-recovery firms sent misleading solicitations. You don’t need to pay or sign with one.
Key Takeaway: There’s no Mallinckrodt Adderall fund, recall, or payout figure, so any dollar amount attached to this name is unverified.
Did Mallinckrodt’s bankruptcy wipe out Adderall claims?
Bankruptcy limited what states can collect from Mallinckrodt, but it doesn’t confirm any Adderall patient claim.
Mallinckrodt filed its second Chapter 11 case on August 28, 2023, in Delaware. Its SEC filings describe a limit. The company says its 2023 plan shields it from monetary damages in the pricing case.
On February 24, 2026, a Connecticut federal judge ruled for Mallinckrodt on that point. Law360 reported that bankruptcy blocked the states’ monetary claims.
Think of a restaurant that restructures after debt trouble. Old tabs get wiped, yet inspectors can still order changes.
Injunctive relief is a different matter. The company’s filings say it can’t estimate whether a court might order changes to its conduct. What the bankruptcy means for private plaintiffs isn’t confirmed in the filings we reviewed.
Who may qualify for a claim tied to Mallinckrodt Adderall?
No one can file a Mallinckrodt Adderall claim today, because no claims process exists.
The open end-payer settlement is a different program. You may qualify if you paid for covered generics between May 2009 and December 2019.
Covered groups include:
- Consumers who paid all or part of the cost, including copays and coinsurance
- Health insurers that reimbursed those costs
- Employer plans with self-funded drug benefits
- Union benefit funds
Pharmacies, wholesalers, and distributors belong to a separate direct purchaser class.
Whether mixed amphetamine salts appear on the covered list isn’t confirmed. Check the full drug list on the official end-payer settlement website before you assume anything.
| Program | Who it’s for | Money | Deadline |
|---|---|---|---|
| End-payer class action | Consumers and health plans | $533 million | November 9, 2026 |
| State attorneys general program | Individual consumers | About $96.5 million | March 8, 2027 |
Filing in one program doesn’t file you in the other.
How do you file a generic drug price-fixing claim by November 9, 2026?
Claims must be filed online or postmarked by November 9, 2026.
Follow these steps:
- Ask each pharmacy you used for a purchase history covering 2009 to 2019.
- Open the covered drug list on the official end-payer settlement website.
- Check whether any of your medicines appear on it.
- Choose the consumer path or the third-party payer path.
- List each covered generic you paid for.
- Attach pharmacy records, receipts, or insurer statements.
- Submit online, or mail the form postmarked by November 9, 2026.
- Save your confirmation.
Filing is free. Don’t pay a claims-recovery firm, because class counsel warned the court about misleading pitches.
Dates can change by court order. Confirm them on the official settlement website before you file.
Key Takeaway: The only open claim near this topic is the generic drug end-payer settlement, which closes November 9, 2026 and requires purchase records.
How do you prove which company made your Adderall?
Ask your pharmacy for the National Drug Code, because its first segment names the labeler.
A HRSA notice lists SpecGx LLC, a Mallinckrodt company, under labeler codes 00406 and 23635. Compare that with one drug database that lists Sandoz mixed amphetamine salts under 00185.
| Labeler | Example code prefix |
|---|---|
| SpecGx (Mallinckrodt) | 00406 or 23635 |
| Sandoz | 00185 |
Pharmacies often switch suppliers between refills. Your bottle might name Mallinckrodt one month and another maker the next.
Record these details for every fill:
- Pharmacy name and fill date
- Manufacturer on the label or stock bottle
- NDC and lot number
- Strength and quantity
- The date you first noticed any change
Keep the bottles if you can. Dates matter, because they show when a manufacturer changed.
Can you sue Mallinckrodt if your generic Adderall didn’t work?
A patient case needs proof of a defect or harm, not just a weaker feeling.
Effects vary by person. Sleep, other medicines, dose, and inactive ingredients can all change how a tablet feels.
In the 2014 Concerta matter, FDA said it found no serious safety concerns. It still downgraded the products over a therapeutic equivalence question.
A lawyer would typically want records that tie a specific lot to a specific problem:
- Prescription and pharmacy records
- Bottles showing the NDC and lot number
- Prescriber notes with dates
- Lab testing, if any exists
- Any adverse event report you filed with FDA
Deadlines to sue vary by state and aren’t confirmed here. If you had documented harm, a licensed attorney can check the rules that apply to you.
What is the latest news in the generic drug price-fixing case?
The pricing case is still pending in 2026, with new settlements and no Mallinckrodt resolution.
| Date | Development |
|---|---|
| January 23, 2026 | Final approval of the $200 million Sun/Taro end-payer settlement |
| February 2, 2026 | States sue Novartis and Sandoz over 31 more generics |
| February 24, 2026 | Connecticut judge rules on Mallinckrodt’s bankruptcy defense to states’ money claims |
| August 2026 | 43 states and territories announce a Sandoz deal in principle |
| October 1 to 2, 2026 | 48 attorneys general announce a final $400 million Sandoz deal and seek court approval |
Reports disagree on the August figure. One outlet reported $450 million, while another reported $400 million. Check the attorneys general announcement for the number.
Keenova’s report for the period ended June 30, 2026 still lists the pricing MDL among its legal proceedings.
When will generic drug settlement payments be sent?
No payment date has been announced as of early October 2026.
Claims close November 9, 2026. The administrator then reviews them and calculates pro rata payments.
It works like a delayed tax refund. Filing starts the clock, but processing sets the timeline. Nothing we found gives a firm month.
Payment date: Not yet announced.
Litigation continues against defendants that haven’t settled. More settlements are possible, but none involving Mallinckrodt is confirmed.
Why is Mallinckrodt named in a case that mentions Adderall?
Plaintiffs allege generic makers coordinated prices and customers for amphetamine salts and other drugs.
The MDL was created in August 2016. It alleges a price-fixing and customer allocation conspiracy beginning around July 2009.
The case now spans dozens of drugmakers and more than 200 generic drugs, per Mallinckrodt’s own SEC filing. A filed complaint lists amphetamine salts (Adderall) in its Mallinckrodt section.
Those are allegations, not findings. Mallinckrodt says it disagrees with the plaintiffs’ account of the facts and law.
The defense group filed joint summary judgment motions on November 22, 2024. Plaintiffs responded on February 20, 2025.
Does Mallinckrodt still make generic Adderall in 2026?
Drug database listings from August 2026 still show SpecGx mixed amphetamine salts products on the market.
Adderall is a brand name. Mallinckrodt’s products are generic mixed amphetamine salts.
Mallinckrodt merged with Endo in 2025. On November 10, 2025, the combined company spun its generics and sterile injectables businesses into Par Health. The branded company now operates as Keenova Therapeutics.
Whether the SpecGx label now sits inside Par Health isn’t confirmed in the filings we reviewed. Keenova also sold its Percocet and Endocet businesses to Par Health, closing July 31, 2026.
Check which legal entity a notice names. The label on your bottle may not match the company named in a court case.
Key Takeaway: Mallinckrodt’s generics business was spun into Par Health in 2025, so verify which company any notice actually names.
Is the Mallinckrodt Concerta case the same as the Adderall lawsuit?
No. The 2014 FDA action involved generic Concerta, a methylphenidate drug, not mixed amphetamine salts.
| Item | Concerta matter | Adderall rumor |
|---|---|---|
| Active drug | Methylphenidate ER | Mixed amphetamine salts |
| FDA action | Rating changed from AB to BX on November 13, 2014 | None verified |
| Court | Mallinckrodt sued FDA in Maryland on November 17, 2014 | No dedicated docket found |
| Payout | None | None |
FDA said it received more than 200 lack-of-effect complaints since 2012. Mallinckrodt said 68 events were confirmed lack-of-efficacy cases and stood by its product’s quality.
A BX rating means the data were insufficient to determine therapeutic equivalence. It isn’t a safety finding.
A Maryland federal court sided with FDA in 2015, and that decision was appealed. In October 2016, FDA proposed withdrawing approval of both generic versions. We didn’t confirm how that proceeding ended.
What Happens Next
- November 9, 2026: The end-payer claim deadline for the Sandoz, Sun/Taro, and Apotex/Heritage settlements.
- Not yet announced: The payment date for those end-payer settlements.
- Pending court approval: The 48 attorneys general’s $400 million Sandoz deal awaits approval in Connecticut federal court.
- March 8, 2027: The claim deadline for the state attorneys general consumer program.
- Not yet confirmed: Any ruling, trial date, or settlement involving Mallinckrodt in the pricing case.
Frequently Asked Questions
Is there a Mallinckrodt Adderall class action lawsuit?
No dedicated Mallinckrodt Adderall class action is confirmed as of October 2026.
Mallinckrodt is a defendant in the generic drug price-fixing litigation, MDL 2724.
That case concerns alleged pricing conduct, not whether the pills work.
Can I get money for Mallinckrodt generic Adderall not working?
No verified payout program exists for that complaint.
Individual legal rights depend on your records and facts.
Talk to a licensed attorney if you had documented harm.
Why do people think Mallinckrodt Adderall was recalled?
They’re mixing it up with FDA’s 2014 action on Mallinckrodt’s generic Concerta.
That drug is methylphenidate, not amphetamine salts.
No Mallinckrodt mixed salts recall turned up in the sources we checked.
Does Mallinckrodt’s bankruptcy end the pricing case against it?
Not entirely, but it limits money claims.
The company says its 2023 plan shields it from monetary damages in the case.
The filings don’t say what that means for private plaintiffs.
Can Adderall users file in the generic drug price-fixing settlement?
It’s not confirmed that amphetamine salts are on the covered list.
Check the drug list on the official end-payer settlement website before filing.
The claim deadline is November 9, 2026.
How do I know if my Adderall is made by Mallinckrodt?
Ask your pharmacy for the manufacturer and National Drug Code.
SpecGx, a Mallinckrodt company, uses labeler codes 00406 and 23635.
Save the lot number from your bottle.
Should I stop taking Mallinckrodt generic Adderall if it feels weaker?
Don’t change or stop your dose on your own.
Tell your prescriber what changed and when.
Ask your pharmacist which manufacturer filled each refill.
How do I avoid generic drug settlement scams?
Use only the official settlement website and court-approved notices.
Filing is free, and you don’t need a claims-recovery firm.
Never pay a fee or share bank details to unlock a payout.
Check your pharmacy records before you chase any Adderall payout rumor. Ask which manufacturer filled each prescription, and write down the NDC.
Then review the covered drug list on the official end-payer settlement website. The deadline is November 9, 2026.
